Anne Luetkemeyer, MD

Phone: 415-476-4082 ext. 130
UCSF Box: 0874
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start End
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy Merck Sharp & Dohme Corp United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
ASN100-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects Medpace, Inc United States Infectious Disease, Pharmacology and Drug Treatment
M14-730 (EXPEDITION-2): A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection AbbVie Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
GSK_201585: Phase III, randomized, multicenter, parallel-group, non inferiority, open-label study evaluating the efficacy, safety, & tolerability of switching to long-acting cabotegravir plus long acting rilpivirine from current INI,NNRTI, or PI-based ART GlaxoSmithKline United States HIV/AIDS, Pharmacology and Drug Treatment
GS-US-380-4030: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Co Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
MK-3682B-037-00A: Phase 3 Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection Merck Sharp & Dohme Corp United States Infectious Disease, Pharmacology and Drug Treatment
Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men NIH National Institute of Allergy and Infectious Disease United States Sexually Transmitted Infections (STIs), Zoonosis, Emerging Disease, and Drug Resistance
Project Sponsor Location(s) Topics Start End
A Probe to Evaluate the Safety, Tolerability & Immunogenicity of the MRK Adenovirus Serotype 5 Vector Human Immunodeficiency Virus Type 1 gag Vaccine in HIV-1 Infected Merck and Co., Inc. United States HIV/AIDS
A phase III trial to investigate the efficacy, tolerability & safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects w/ limited to no treatment options Tibotec Pharmaceuticals Ltd United States HIV/AIDS, Pharmacology and Drug Treatment
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of a Novel CCR5 Antagonist, UK427,857, for the Treatment of Antiretroviral-Experienced HIV-1-Infected Subjects Pfizer United States HIV/AIDS, Pharmacology and Drug Treatment
Tibotec TMC125-C214: Early Access of TMC125 in Combination with Other Antiretrovirals in Treatment-Experienced HIV-1 Infected Subjects with Limited Treatment 0ptions Tibotec Pharmaceuticals Ltd United States HIV/AIDS, Pharmacology and Drug Treatment
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia Bristol-Myers Squibb Company United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
Cepheid 077B-C: Evaluation of the Xpert® MTB/RIF Assay Cepheid Uganda; United States Tuberculosis
Metabolic Substudy of A5257, CIMT/FMD Repeat Scans (ACTG A5260s:) Social & Scientific Systems, Inc. United States HIV/AIDS
Pfizer A4001027: Observational Phase Extension Pfizer United States HIV/AIDS, Pharmacology and Drug Treatment
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy (ACTG) A5260s Social & Scientific Systems, Inc. United States HIV/AIDS
Tobira 652-2-202 Pre-Clinical Trial Cost Agreement Tobira Therapeutics United States HIV/AIDS, Pharmacology and Drug Treatment
ACTG, AIDS Clinical Trials Research Group - A5289 and A5255 Brigham and Women's Hospital United States HIV/AIDS
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C Bristol-Myers Squibb Company France; Germany; Hungary; Spain; Argentina Sexually Transmitted Infections (STIs)
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects Cepheid United States HIV/AIDS, Tuberculosis
Gilead GS-US-236-0102 Gilead Sciences, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
DAIDS A5298 Study: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men Merck and Co., Inc. Brazil; Puerto Rico HIV/AIDS, Cancer/Oncology
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Bristol-Myers Squibb Company France; Germany; Italy; Russia; Spain; United Kingdom; Argentina; Puerto Rico; Canada; Australia HIV/AIDS
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 plus Ribavirin for 12 Weeks in Chronic Genotype 2 and 3 Hepatitis C Virus (HCV) Coinfected Subjects (GS-US-334-0123) Gilead Sciences, Inc. United States Sexually Transmitted Infections (STIs)
GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti Gilead Sciences, Inc. United States Infectious Disease, Pharmacology and Drug Treatment
ViiV Healthcare A4001098 Pfizer United States
GS-US-183-0130: A Phase 3, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents in the Treatment of HIV-1 Infected Subjects Gilead Sciences, Inc. United States HIV/AIDS
A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 weeks in Subjects with Chronic HCV and HIV-1 Coinfection Gilead Sciences, Inc. United States Infectious Disease, HIV/AIDS, Pharmacology and Drug Treatment
ACTG A5294: A Prospective, Phase III Open-Label Study of Response-Guided Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects Merck and Co., Inc. United States HIV/AIDS
Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic HCV and HIV AbbVie Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination with Ribavirin and Daclatasvir for Treatment of Chronic HCV Infection with Treatment Naïve Genotypes 1, 2, 3 or 4 in Subjects Coinfected with HIV-1 Bristol-Myers Squibb Company United States HIV/AIDS
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Gilead Sciences, Inc. United States Sexually Transmitted Infections (STIs)
Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Subjects with Chronic Hepatitis C Gilead Sciences, Inc. United States Sexually Transmitted Infections (STIs)